Thibault Viennet

Oct 26, 2023 | nature.com | Christoph Gorgulla |Sara Marchese |Sergio Valente |Thibault Viennet |Melissa Ronan |Matthew Rees | +5 more

AbstractNADPH oxidases (NOXs) are transmembrane enzymes that are devoted to the production of reactive oxygen species (ROS). In cancers, dysregulation of NOX enzymes affects ROS production, leading to redox unbalance and tumor progression. Consequently, NOXs are a drug target for cancer therapeutics, although current therapies have off-target effects: there is a need for isoenzyme-selective inhibitors.